Abstract:
Polymeric conjugates of a polymeric backbone formed of a plurality of backbone units and having attached to portions of the backbone units two or more therapeutically active agents, or one or more therapeutically active agents and a NCAM targeting moiety, are disclosed. Uses of such polymeric conjugates in treating and/or monitoring cancer and/or medical conditions associated with angiogenesis are also disclosed.
Abstract:
Polymeric conjugates of a polymeric backbone formed of a plurality of backbone units and having attached to portions of the backbone units two or more therapeutically active agents, or one or more therapeutically active agents and a NCAM targeting moiety, are disclosed. Uses of such polymeric conjugates in treating and/or monitoring cancer and/or medical conditions associated with angiogenesis are also disclosed.
Abstract:
The present disclosure provides heteroarene-based drug derivatives having a “clickable” ketone group, as well as conjugates of said drug derivatives with targeting moieties capable of binding to extracellular antigens; and pharmaceutical compositions comprising them.
Abstract:
Described herein are novel polyglycerol-amine polymeric nanocarriers in complex with microRNAs and their uses in the treatment of cancer, in particular glioblastoma. Delivery of the polymeric nanocarriers in complex with microRNAs in cell lines and in vivo inhibited cell proliferation, cell cycle progression, cell migration and tumor growth.
Abstract:
Conjugates of a polymer having attached thereto an angiogenesis targeting moiety and a therapeutically active agent such as an anti-cancer agent or anti-angiogenesis agent, and processes of preparing same are disclosed.Pharmaceutical compositions containing these conjugates and uses thereof in the treatment of angiogenesis-related medical conditions such as cancer and cancer metastases are also disclosed.
Abstract:
Conjugates of polymers or copolymers having attached thereto an anti-angiogenesis agent and a bisphosphonate bone targeting agent, and processes of preparing same, are disclosed.Pharmaceutical compositions containing these conjugates and uses thereof in the treatment of bone related disorders are also disclosed.
Abstract:
The present disclosure provides heteroarene-based drug derivatives having a “clickable” ketone group, as well as conjugates of said drug derivatives with targeting moieties capable of binding to extracellular antigens; and pharmaceutical compositions comprising them.
Abstract:
Novel fluorogenic compounds designed such that upon a chemical event, compounds capable of emitting NIR light are generated, are disclosed. The compounds comprise two or more acceptor-containing moieties and a cleavable donor-containing moiety, being in complete pi-electrons conjugation and being such that no delocalization of pi-electrons is enabled. Also disclosed are fluorescent compounds generated upon subjecting the fluorogenic compounds to a chemical event (e.g., deprotonation). Also disclosed are uses of the fluorogenic compounds as NIR probed with a Turn-ON mechanism in monitoring presence and/or level of various analytes.
Abstract:
Polymeric conjugates of a polymeric backbone formed of a plurality of backbone units and having attached to portions of the backbone units two or more therapeutically active agents, or one or more therapeutically active agents and a NCAM targeting moiety, are disclosed. Uses of such polymeric conjugates in treating and/or monitoring cancer and/or medical conditions associated with angiogenesis are also disclosed.